Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040659 · ClinicalTrials.gov registry record
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
A clinical trial of Healthy and Influenza, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05040659: Active study of Healthy and Influenza, sponsored by Massachusetts General Hospital.
NCT05040659 is a study of Healthy and Influenza that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,000 participants, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05040659, a study of Healthy and Influenza, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.
Primary Outcome
The Aromha Smell Test is a battery of 18 odors across 6 smell cards. The subject smells each of the 3 scents per card to determine smell intensity, identification, and discrimination. Increased number of correct responses indicates better sense of smell. We will evaluate previously diagnosed anosmic patients.
Conditions Studied
Interventions
- DEVICE AROMHA Longitudinal Smell Test
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT05040659 still lists
NCT05040659 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (55% higher).
The record links to 6 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which AROMHA Longitudinal Smell Test is the first listed.
NCT05040659 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05040659 about?
NCT05040659 is a clinical study titled "Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2". The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring...
What is the current status of trial NCT05040659?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2022-11-14. Estimated completion is 2027-12-31.
What conditions does trial NCT05040659 study?
This clinical trial studies the following conditions: Healthy, Influenza, COVID-19 Respiratory Infection, PASC Post Acute Sequelae of COVID 19, Anosmia.
What interventions are being tested in trial NCT05040659?
The interventions under investigation include: AROMHA Longitudinal Smell Test (DEVICE).
Who is sponsoring clinical trial NCT05040659?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05040659 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05040659's enrollment target sits among peer trials
1,000 29th of 1090 higher than 1,061 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI